Bayer, Drug Prices & Medicare Spending
Bayer manufactures 8 drugs tracked by Medicare Part D with total spending of $3.0B.
Bayer Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Nubeqa | Darolutamide | $7,910.00 | Yes |
| 2 | Adempas | Riociguat | $9,500.00 | Yes |
| 3 | Stivarga | Regorafenib | $12,321.00 | Yes |
| 4 | Kerendia | Finerenone | $399.00 | Yes |
| 5 | Nexavar | Sorafenib | $8,357.00 | Yes |
| 6 | Betaseron | Interferon Beta-1b | $5,571.00 | Yes |
| 7 | Ciprofloxacin | Ciprofloxacin | $14.00 | Yes |
| 8 | Nifedipine | Nifedipine ER | $18.00 | Yes |
Frequently Asked Questions
Bayer manufactures 8 drugs tracked by Medicare Part D, with total annual spending of $3.0B.
Stivarga (Regorafenib) is the most expensive at $12,321.00 per claim.
8 of 8 Bayer drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.
Source: CMS Medicare Part D Spending, 2026.